Durable, potentially curative cell and gene therapies with short term treatment regimens promise to transform care for some conditions, but present significant financial risks and uncertain long term efficacy.
One of the biggest challenges to new financing models for innovative therapies the 1990 Medicaid “best price” rules, which ensures that the Medicaid program receives discounts at least as large as commercial payers. But CMS is implementing a new rule in January 2023 for tiered MBP reporting based on performance.
Important questions about implementation, participation, and pricing persist. Panelists in this webinar will bring both quantitative analysis and practical experience perspectives to bear on the issues.
July 21, 2022
11:00am – 12:00pm Eastern
Panel discussion and Q&A
Web conference
In this one hour webinar you will:
- Explore the use of alternative payment approaches managing financial risk associated with curative therapies
- Learn how the new CMS rule could lead to widespread feasibility and adoption of Value-Based Purchasing Arrangements
- Learn what challenges remain and how they can be overcome by a combination of clever implementation and eventually, legislative enhancements to the Medicaid Drug Rebate Program
Ideal for:
- Biopharmaceutical market access and government affairs
- Payer pharmacy benefits and contracting
- Employer benefits managers and benefits consultants
- Specialty pharmacy and channel intermediaries
- Policymakers
- Patient advocates
- …and all those interested in drug payment innovation

Panelists

Mike Ciarametaro, MBA
Vice President Research,
National Pharmaceutical Council

Dorothy Hoffman
External Engagement and Access Policy Lead,
Pfizer

Gail Ryan, PharmD
Director, Pharmaceutical Transformation, Clinical Innovation
Point32Health

Mark Trusheim, MS
Strategic Director, NEWDIGS;
Visiting Scientist, Sloan School of Management,
Massachusetts Institute of Technology
Registration
Thursday, July 21
11:00am – 12:00pm Eastern
Web conference: Panel discussion and Q&A
Registration is free